Acasti Pharma ROA 2014-2024 | GRCE
Current and historical return on assets (ROA) values for Acasti Pharma (GRCE) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
| Acasti Pharma ROA - Return on Assets Historical Data |
| Date |
TTM Net Income |
Total Assets |
Return on Assets |
| 2024-06-30 |
$-0.01B |
$0.07B |
-14.81% |
| 2024-03-31 |
$-0.01B |
$0.07B |
-16.00% |
| 2023-12-31 |
$-0.04B |
$0.08B |
-49.67% |
| 2023-09-30 |
$-0.04B |
$0.08B |
-46.11% |
| 2023-06-30 |
$-0.04B |
$0.07B |
-43.08% |
| 2023-03-31 |
$-0.04B |
$0.08B |
-38.91% |
| 2022-12-31 |
$-0.02B |
$0.12B |
-14.63% |
| 2022-09-30 |
$-0.02B |
$0.12B |
-14.72% |
| 2022-06-30 |
$-0.01B |
$0.13B |
-9.84% |
| 2022-03-31 |
$-0.01B |
$0.13B |
-9.46% |
| 2021-12-31 |
$-0.01B |
$0.11B |
-13.48% |
| 2021-09-30 |
$-0.01B |
$0.12B |
-16.18% |
| 2021-06-30 |
$-0.02B |
$0.06B |
-43.37% |
| 2021-03-31 |
$-0.02B |
$0.06B |
-63.49% |
| 2020-12-31 |
$0.00B |
$0.03B |
13.79% |
| 2020-09-30 |
$-0.01B |
$0.01B |
-27.91% |
| 2020-06-30 |
$-0.02B |
$0.02B |
-83.17% |
| 2020-03-31 |
$-0.03B |
$0.02B |
-90.91% |
| 2019-12-31 |
$-0.06B |
$0.03B |
-177.42% |
| 2019-09-30 |
$-0.05B |
$0.03B |
-131.43% |
| 2019-06-30 |
$-0.04B |
$0.03B |
-133.33% |
| 2019-03-31 |
$-0.04B |
$0.04B |
-132.20% |
| 2018-12-31 |
$-0.03B |
$0.05B |
-129.29% |
| 2018-09-30 |
$-0.03B |
$0.02B |
-181.33% |
| 2018-06-30 |
$-0.02B |
$0.02B |
-110.53% |
| 2018-03-31 |
$-0.02B |
$0.02B |
-94.44% |
| 2017-12-31 |
$-0.01B |
$0.02B |
-70.27% |
| 2017-09-30 |
$-0.01B |
$0.02B |
-57.97% |
| 2017-06-30 |
$-0.01B |
$0.02B |
-45.07% |
| 2017-02-28 |
$-0.01B |
$0.02B |
-43.24% |
| 2016-11-30 |
$-0.01B |
$0.02B |
-43.24% |
| 2016-05-31 |
$-0.01B |
$0.02B |
-38.10% |
| 2016-03-31 |
$-0.01B |
$0.02B |
-28.99% |
| 2015-12-31 |
$-0.01B |
$0.02B |
-21.82% |
| 2015-09-30 |
$-0.00B |
$0.03B |
-3.28% |
| 2015-06-30 |
$-0.00B |
$0.03B |
-8.96% |
| 2015-03-31 |
$-0.00B |
$0.03B |
-2.74% |
| 2014-12-31 |
$-0.00B |
$0.04B |
-5.10% |
| 2014-06-30 |
$-0.01B |
$0.04B |
-22.02% |
| 2014-03-31 |
$-0.01B |
$0.04B |
-42.55% |
| 2013-12-31 |
$-0.01B |
$0.03B |
-60.27% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-GENERIC DRG |
$0.033B |
$0.000B |
|
Acasti Pharma Inc. is a biopharmaceutical company. It is focused on research, development and commercialization of krill oil based forms of omega-3 phospholipid therapies. CaPre (R), Acasti's only prescription drug candidate, is being developed to help prevent and treat hypertriglyceridemia. ONEMIA (R) is a medical food and currently Acasti's only commercialized product. Acasti Pharma Inc. is headquartered in Laval, Canada.
|
